Nicorandil
- Generic Name
- Nicorandil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9N3O4
- CAS Number
- 65141-46-0
- Unique Ingredient Identifier
- 260456HAM0
- Background
Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used ...
- Indication
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
- Associated Conditions
- Angina Pectoris
- Associated Therapies
- -
China-Administration of Nicorandil Group（CHANGE）
- Conditions
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT03445728
- Locations
- 🇨🇳
CHINA, Beijing, China
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT03252665
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, ShangHai, China
Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 8
- Registration Number
- NCT03010423
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Taipei Medical University WanFang Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02809456
Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT02449070
- Locations
- 🇰🇷
Pusan National University Hospital, Pusan, Korea, Republic of
Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Xuzhou Central Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02435797
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou, Jiangsu, China
Efficacy Study of Nicorandil on Neointima
- Conditions
- Interventions
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Zhang Ying Qian
- Target Recruit Count
- 48
- Registration Number
- NCT02328521
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Mashhad University of Medical Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT02254252
Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil
- Conditions
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Kumamoto University
- Target Recruit Count
- 268
- Registration Number
- NCT01475123
- Locations
- 🇯🇵
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Ferozsons Laboratories Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01397994
- Locations
- 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, Sind, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.